Navigation Links
Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
Date:5/4/2009

BOSTON, May 4 /PRNewswire/ -- Johnston Blakely & Company, LLC, a Boston-based life science investment bank, is pleased to announce that John L. Brooks, III has joined the firm as senior advisor. In this role, Mr. Brooks will participate with the firm on internal and client-related activities including private equity placements and merger & acquisition advisory services, with a particular focus on medical device transactions. "We are thrilled to welcome John Brooks to the Johnston Blakely family," remarked Johnston Blakely founder Benjamin Conway. "Not only does John bring to the firm and its clients a track record of success in both venture capital and the medical device industry, but his decision to join us is also a strong endorsement of Johnston Blakely and its capabilities."

John Brooks co-founded the venture capital firm Prism Venture Partners. During his ten-year tenure with Prism, the firm raised $1.25 billion across six venture funds. While with Prism, Mr. Brooks led the firm's healthcare investment activities including its role in the creation of companies such as Insulet Corporation. His previous experience also includes senior management positions at Pfizer, both with Pfizer/Valleylab as General Manager and with Pfizer/Strato. Mr. Brooks has held several vice president of finance and operations positions at successful venture-backed companies and spent over 10 years in public accounting and consulting focused on supporting venture backed entrepreneurs.

In addition to his current involvement on the boards of certain Prism portfolio companies, John Brooks is vice chairman of the Board of Trustees of the Joslin Diabetes Center where he is also chairman of the finance committee, a member of the steering committee of Mass Medic's MedTech Ignite (Inspiring Growth in New Innovative Technology Enterprises) program and is on the Draper BioAdvisory Board.

About Johnston Blakely & Company

Johnston Blakely & Company, LLC is a Boston-based investment bank offering private equity placement and merger & acquisition-related financial advisory services to companies in the life science sector. The firm incorporates the venture capital tradition of comprehensive company involvement into investment banking engagements to deliver superior results for its clients. More than investment banking...inVenture banking(TM).

Johnston Blakely is a registered broker/dealer and member of FINRA/SIPC.


'/>"/>
SOURCE Johnston Blakely & Company, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UMass Boston Opens Venture Development Center to Expand R&D Activity
2. Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
3. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
4. CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
5. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
6. Cynvec to Present at the BIO National Venture Conference
7. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
8. Merck Serono Launches Strategic Venture Capital Fund
9. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
10. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
11. Alltech, Mitsui and Asahi Breweries Create New Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell ... the development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease. ... Dr. Jeanne Loring at The Scripps Research Institute in San Diego, CA. ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week ... talk on its first-in-class technologies for tissue stem cell counting and expansion to ... Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention ...
(Date:4/27/2016)... Boston (PRWEB) , ... April 27, 2016 , ... ... driven by semantic web technology, today announced that it has been named to The ... life sciences, financial services and other markets, Cambridge Semantics serves the needs of end ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):